Geographical Analysis North America is expected to hold 42.5% of the global glucagon-like peptide 1 (GLP-1) market in 2024 North America is expected to hold 42.5% of the global glucagon-like peptide 1 (GLP-1) market in 2024 The rising rates of obesity and type 2 diabetes in North America are driving the demand for effective treatment options
The gastric administration of TO also increases active GLP-1 levels after 10 min, and followed by a decrease to basal levels at 60 min
If a job or daily task involves lifting or carrying, it may help to use tools or ask for help to avoid strain
DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 USD 170.75 BN MARKET SIZE, 2033 OVERVIEW Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period
If the evaluating clinician determines a patient is not eligible, a full refund is issued within 2448 hours per the platform's published FAQ
Are you fighting obesity or looking for a good weight loss method
